Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Nailbiter2on Oct 01, 2024 1:12pm
74 Views
Post# 36248595

RE:RE:New Press Release - StageZero Life Sciences, Ltd Announces Q2 2024 Financial Results and Operational Update

RE:RE:New Press Release - StageZero Life Sciences, Ltd Announces Q2 2024 Financial Results and Operational UpdateIt's a waste of time trying to explain the the minions of SH.
All I have to add is "it ain't over 'till the fat lady sings".
EOM


LithLover wrote: If Tripp just wanted to keep earning his high salary as many bashers here think thats his only purpose, than why try to relist.  Just stay delisted and milk it for all it's worth. Why even file quarterly reports or PRs or suggest even attempting to relist.  It's not trading so why send our press releases if you dont plan on relisting go quiet and just draw a salary.

If he just wants to issue more shares he could have done that with the GEM financing?  Issue shares and do a reverse split.  It's in place  for 13 more months yet he commented that it was not beneficial to utilize the financing at this share price level.  So hes aware of dilution and the impact it would have so relisting is not about issuing shares.  

Nov 2022:  StageZero has the right, but not the obligation, to draw down under the CC for a term of 3 years.

So what is his motivation to continue to file quarterly reports, send out press releases if not to get relisted?  Why relist only to have the share price drop, he wont utilize the funding at an even lower price so why even bother?  Options are way above this price.  Does he expect to get relisted and grow the share price?  Only thing that makes sense   But he must realize after all these years that to drive the share price it can only happen with confirmed significant partnerships (not 1 man companies) and reported revenues. He's lost his audience with years of fluff PRs about cash flow positive, partnerships, and large employer groups blah blah.  The only way share price moves up is big news and reported revenue increases. Anything less and this drops even further given the delisting and lack of funds.

I can't see the point in relsiting unless there are significant partners announced to hold up the share price prior to the relist. Than significant increases in Q3 and Q4 revenues.   If the intention is to request a relist at the end of the month would expect something coming in the next few days/weeks. And not more video calls or cooking classes but significant testing partners.  Anything outside of increased Aristotle numbers does nothing.   COC may be keeping the lights on but if Aristotle doesnt take off there is no growing this share price and basically no reason to ever relist.  




<< Previous
Bullboard Posts
Next >>